Updated on 3 December 2013
"With the rise of resistant superbugs, we desperately need to find new ways to combat infectious diseases and I am hopeful, based on our early findings, that research from the ithree institute will make a contribution to that urgent quest" added Professor Charles.
Subject to meeting milestones, Auspherix will seek further investment or industry partnerships to move the novel antibiotics into pre-clinical and clinical development, potentially for broad spectrum use.
This is the second investment by MRCF in technology emerging from the ithree institute. It invested $1.14 million (AU$1.25 million) in Helmedix in February 2013.
The ithree institute was launched in 2010 and joined the MRCF in 2011.